Summary:
We talk with Chris Moreau — CEO of Algernon Pharmaceutics— about psychedelics for neural growth, drug repurposing, and the path to clinical trial approvals.
Highlights:
— NUGGET AND A NOODLE: UK prime minister ponders psychedelics, tax revenue from magic mushrooms (0:28)
— psychedelics helping brain neurons grow (2:20)
— can psychedelics heal the brain or make you smarter? (8:40)
— drug repurposing to focus on stroke, chronic cough and IPF (12:37)
— the brain reboot (19:50)
— phase 1 trials coming for Algernon (25:01)
— SOUL SEARCH: attention vs curiosity (26:30)
Chris Moreau:
He is a seasoned business professional in the life sciences sector with a strong background in biotechnology research, business development and a deep expertise in the capital markets. He has raised in excess of $40 million from the capital markets and has over 30 years of senior management experience in private & publicly traded company environments.
Find Chris here:
https://algernonpharmaceuticals.com/
